Loading viewer...
conference
Format: PDF conference
Revance Therapeutics presented its 2024 strategic priorities and commercial update at the JP Morgan Healthcare Conference, focusing on DAXXIFY® expansion into therapeutics including cervical dystonia, RHA® dermal fillers pipeline growth, and path to positive adjusted EBITDA. The presentation covers commercialization strategy, market opportunities, and financial guidance for 2024.
conference
30 Pages
Absa Group
Bonneville Power Administration Provider of Choice Policy 2023
conferenceconference
23 Pages
Bonneville Power Administration
FLYHT Aerospace Solutions 2022 GCFF Conference Presentation
conferenceconference
21 Pages
FLYHT Aerospace Solutions